Kidney Week

Abstract: TH-PO217

Peritoneal Dialysis Mineral Metabolism Disorders: Results from the BRAZPDII

Session Information

• Bone and Mineral Metabolism: Clinical - I
  October 25, 2018 | Location: Exhibit Hall, San Diego Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Bone and Mineral Metabolism

• 402 Bone and Mineral Metabolism: Clinical

Authors

• Truyts, Cesar Augusto madid, Universidade de São Paulo, São Paulo, Brazil

Cesar Augusto madid Truyts,

• Nunes, Lucas Acatauassu, Universidade de São Paulo, São Paulo, Brazil

Lucas Acatauassu Nunes,

• Custodio, Melani, Universidade de São Paulo, São Paulo, Brazil

Melani Custodio,

• Moyses, Rosa M.A., Universidade Nove de Julho, São Paulo, Brazil

Rosa M.A. Moyses,

• Pecoits-Filho, Roberto, Pontificia Universidade Catolica do Parana, Curitiba, Paraná, Brazil

Roberto Pecoits-Filho,

• Jorgetti, Vanda, Universidade de São Paulo, São Paulo, Brazil

Vanda Jorgetti,

• Moraes, Thyago Proença de, Pontificia Universidade Catolica do Parana, Curitiba, Paraná, Brazil

Thyago Proença de Moraes,

Background

Few studies evaluate mineral and bone disorders (MBD) in patients treated with peritoneal dialysis (PD), and the main guideline guiding their treatment were based on studies performed in patients treated with hemodialysis. BRAZPDII is a cohort of patients from 114 dialysis centers in Brazil, which contains data from 9.905 patients on peritoneal dialysis. We analyzed biochemical markers related to MBD (calcium (Ca), phosphorus (P) and parathormone (PTH)), categorized patients in accordance with the targets proposed guideline Kidney Disease: Improving Global Outcomes (KDIGO),and compared the survival index between the groups which maintained the biochemical markers within or without the normal ranges

Methods

We recruited 844 patients from BRAZPDII, who had MBD biomarker data, and followed them up for 24 months. Cox proporcional was used to eliminate potencial variable confounders, and Kaplan-Meier estimator was used to compare the survival rate between the groups.

Results

Patients with Ca and P within the normal range using KDIGO definitions (8.4-10.2mg/dL and 3.5-5.5mg/dL, respectively) were associated with lower mortality (p<0.05; HR 1.63 and 1.79, respectively). PTH levels were not associated with mortality, regardless of the ranges proposed by KDIGO guideline (150-600).

Conclusion

Keeping calcium and phosphate within the range as suggested by KDIGO was associated with lower mortality in PD patients. PTH levels were not associated with mortality risks.

Relative risk of mortality and biochemical parameters out of range (KDIGO)

Funding

• Commercial Support –